MET and non-small cell lung carcinoma: Further, phase III SAFFRON trial (NCT05261399) is investigating savolitinib plus osimertinib versus platinum-based doublet chemotherapy in participants with NSCLC (EGFR mutated, c-MET overexpressed and/or MET gene amplified) who have progressed on osimertinib treatment.